PCPeng Chen

Peng Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peng Chen has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Zhi-Jun Jia

    Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Department of Biopharmaceutics, West China School of Pharmacy Sichuan University Chengdu 610041 China

    7 shared publications
  • Yongxiang Zheng

    Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Department of Biopharmaceutics, West China School of Pharmacy

    5 shared publications
  • Xiao‐Qi Liu

    Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Department of Biopharmaceutics, West China School of Pharmacy Sichuan University Chengdu 610041 China

    4 shared publications
  • Xin Wang

    Key Laboratory of Birth Defects and Related Diseases of Women and Children, Children’s Medicine Key Laboratory of Sichuan Province, Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital

    3 shared publications
  • Ying Wu

    Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Department of Biopharmaceutics, West China School of Pharmacy

    3 shared publications
  • Chun Zhang

    Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Department of Biopharmaceutics, West China School of Pharmacy Sichuan University Chengdu 610041 China

    2 shared publications

Latest Publications

  • Open Access

    Reprogramming Imine Reductases for Enantioselective Reduction of Electron-Rich Enamides

    by Xiao-Qi Liu, Ru Li, Jun-Liang Chen, Ye Li, Long Wei, Hongli Wu, Li Li, Ben-Hong Chen, Ying Wu, Si-Jia Liu, et al.

    Imine reductases (IREDs) are powerful biocatalysts to afford valuable enantioenriched amines via the stereoselective reduction of imines. While significant progress has been made in expanding their catalytic capabilities, direct reduction of electron-rich alkenes by IREDs remains a formidable challenge and is unprecedented in biology. Here, we report the reprogramming of an IRED from Sinorhizobium (SinIRED) to catalyze the enantioselective reduction of enamides. Through directed evolution, the final optimized SinIRED-V5 variant is able to reduce a variety of enamides and deliver diverse protected chiral amines in up to 97% yield and >99:1 enantiomeric ratio (e.r.). Mechanistic studies suggest a novel synergistic pathway involving enamine–imine tautomerization followed by NADPH-mediated hydride transfer process. This work expands the catalytic versatility of IREDs and provides the first known example of IRED-catalyzed reduction of electron-rich enamides.


  • Open Access

    Directed Evolution of Nonheme Iron Enzymes for Enantioselective Aminative Difunctionalization of Alkenes

    by Fei Liu, Si-Yi Li, Zi-Shan Fan, Jia-Hua Luo, Xue Zeng, Long Wei, Ye Li, Jia-Yao Li, Yongxiang Zheng, Xin Wang, et al.

    The direct aminative difunctionalization of alkenes offers a powerful strategy for synthesizing valuable amine-containing compounds. However, achieving this transformation enantioselectively remains a significant challenge in both synthetic chemistry and biocatalysis. In this study, we engineered a nonheme iron enzyme, quercetin 2,3-dioxygenase from Bacillus subtilis (BsQueD), to catalyze three distinct alkene aminofunctionalization reactions with high efficiency and enantiocontrol. Through directed evolution, we developed an optimized BsQueD variant capable of producing a wide array of chiral 2-azidoamines, 2-aminothiazolines, and 2-aminooxazolines with up to 72% yield and 99:1 enantiomeric ratio (e.r.). Mechanistic investigations suggest a stepwise radical addition pathway. This work broadens the scope of biocatalytic alkene difunctionalization, providing a sustainable and efficient route for synthesizing diverse chiral primary amines.


  • Engineering Unspecific Peroxygenases for Enantioselective α‐Hydroxylation of β‐Ketoesters

    by Zhen‐Yu Wang, Xin‐Yuan Ma, Ying Wu, Yang Liu, Guang‐Xin Lin, Xiao‐Qi Liu, Chun Zhang, Peng Chen, Yongxiang Zheng, Zhi‐Jun Jia

    Unspecific peroxygenases (UPOs) are promising biocatalysts for selective oxyfunctionalization. Compared to cytochrome P450 enzymes (P450s), the catalytic potential of UPOs has been less investigated, largely due to their limited natural diversity and the challenges associated with their optimization through enzyme engineering. In this study, we engineered an UPO from Aspergillus niger ( Ani UPO) to catalyze the enantioselective α‐hydroxylation of β‐ketoesters, a valuable transformation yet to be realized in biocatalysis. Through enzyme engineering, two Ani UPO variants, Ani UPO‐M3 and Ani UPO‐M6, were developed to produce a wide range of enantioenriched α‐hydroxy‐β‐ketoesters, achieving up to 97% yield, 4140 total turnover number (TTN), and >99:1 enantiomeric ratio (er). The biocatalytic process operates under mild conditions and is scalable for preparative applications. This study broadens the catalytic repertoire of UPOs and enhances their potential for industrial applications.


  • Engineering Unspecific Peroxygenases for Enantioselective α‐Hydroxylation of β‐Ketoesters

    by Zhen‐Yu Wang, Xin‐Yuan Ma, Ying Wu, Yang Liu, Guang‐Xin Lin, Xiao‐Qi Liu, Chun Zhang, Peng Chen, Yongxiang Zheng, Zhi‐Jun Jia

    Unspecific peroxygenases (UPOs) are promising biocatalysts for selective oxyfunctionalization. Compared to cytochrome P450 enzymes (P450s), the catalytic potential of UPOs has been less investigated, largely due to their limited natural diversity and the challenges associated with their optimization through enzyme engineering. In this study, we engineered an UPO from Aspergillus niger ( Ani UPO) to catalyze the enantioselective α‐hydroxylation of β‐ketoesters, a valuable transformation yet to be realized in biocatalysis. Through enzyme engineering, two Ani UPO variants, Ani UPO‐M3 and Ani UPO‐M6, were developed to produce a wide range of enantioenriched α‐hydroxy‐β‐ketoesters, achieving up to 97% yield, 4140 total turnover number (TTN), and >99:1 enantiomeric ratio (er). The biocatalytic process operates under mild conditions and is scalable for preparative applications. This study broadens the catalytic repertoire of UPOs and enhances their potential for industrial applications.


  • Enantioselective Trifluoromethylazidation of Styrenyl Olefins Catalyzed by an Engineered Nonheme Iron Enzyme

    by Hua He, Jia‐Xin Yan, Jian‐Xiang Zhu, Si‐Jia Liu, Xiao‐Qi Liu, Peng Chen, Xin Wang, Zhi‐Jun Jia

    Organofluorines, particularly those containing trifluoromethyl (CF3) groups, play a critical role in medicinal chemistry. While trifluoromethylation of alkenes provides a powerful synthetic route to construct CF3‐containing compounds with broad structural and functional diversity, achieving enantioselective control in these reactions remains a formidable challenge. In this study, we engineered a nonheme iron enzyme, quercetin 2,3‐dioxygenase from Bacillus subtilis (BsQueD), for the enantioselective trifluoromethylazidation of alkenes. Through directed evolution, the final variant BsQueD‐CF3 exhibited excellent enantioselectivity, with an enantiomeric ratio (e.r.) of up to 98 : 2. Preliminary mechanistic studies suggest the involvement of radical intermediates. This work expands biocatalytic organofluorine chemistry by reprogramming metalloenzymes for innovative trifluoromethylation reactions.


  • Enantioselective Trifluoromethylazidation of Styrenyl Olefins Catalyzed by an Engineered Nonheme Iron Enzyme

    by Hua He, Jia‐Xin Yan, Jian‐Xiang Zhu, Si‐Jia Liu, Xiao‐Qi Liu, Peng Chen, Xin Wang, Zhi‐Jun Jia

    Organofluorines, particularly those containing trifluoromethyl (CF3) groups, play a critical role in medicinal chemistry. While trifluoromethylation of alkenes provides a powerful synthetic route to construct CF3‐containing compounds with broad structural and functional diversity, achieving enantioselective control in these reactions remains a formidable challenge. In this study, we engineered a nonheme iron enzyme, quercetin 2,3‐dioxygenase from Bacillus subtilis (BsQueD), for the enantioselective trifluoromethylazidation of alkenes. Through directed evolution, the final variant BsQueD‐CF3 exhibited excellent enantioselectivity, with an enantiomeric ratio (e.r.) of up to 98 : 2. Preliminary mechanistic studies suggest the involvement of radical intermediates. This work expands biocatalytic organofluorine chemistry by reprogramming metalloenzymes for innovative trifluoromethylation reactions.


  • Iron-Catalyzed Primary Amination of C(sp3)–H Bonds

    by Ye Liu, Yu Chen, Yu-Jie Zhao, Guo-Qing Zhang, Yongxiang Zheng, Peiyuan Yu, Peng Chen, Zhi-Jun Jia

    Primary amines are privileged molecules in drug development. Yet, there is a noticeable scarcity of methods for directly introducing a primary amine group into the ubiquitous C(sp3)-H bonds within organic compounds. Here, we report an iron-based catalytic system that enables direct primary amination of C(sp3)-H bonds under aqueous conditions and air. Various types of C(sp3)-H bonds, including benzylic, allylic, and aliphatic ones, can be readily functionalized with high selectivity and efficiency. The broad utility of this method has been further verified by late-stage amination of 11 complex bioactive molecules. Mechanistic studies unveil a protonated iron-nitrene complex as the key intermediate for the C-H bond activation. This work extends the toolbox for direct C(sp3)-H functionalizations, opening up new opportunities for late-stage modifications of organic molecules.